Ivabradine improves survival and attenuates cardiac remodeling in isoproterenol-induced myocardial injury

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F21%3A10427932" target="_blank" >RIV/00216208:11150/21:10427932 - isvavai.cz</a>

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=9t.f7bQz07" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=9t.f7bQz07</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/fcp.12620" target="_blank" >10.1111/fcp.12620</a>

Result language

angličtina

Original language name

Ivabradine improves survival and attenuates cardiac remodeling in isoproterenol-induced myocardial injury

Original language description

This study investigated whether ivabradine, a selective If current inhibitor reducing heart rate (HR), is able to improve survival and prevent left ventricular (LV) remodeling in isoproterenol-induced heart damage. Wistar rats were treated for 6 weeks: controls (n = 10), ivabradine (10 mg/kg/day orally; n = 10), isoproterenol (5 mg/kg/day intraperitoneally; n = 40), and isoproterenol plus ivabradine (n = 40). Isoproterenol increased mortality, induced hypertrophy of both ventricles and LV fibrotic rebuilding, and reduced systolic blood pressure (SBP). Ivabradine significantly increased survival rate (by 120%) and prolonged average survival time (by 20%). Furthermore, ivabradine reduced LV weight and hydroxyproline content in soluble and insoluble collagen fraction, reduced HR and attenuated SBP decline. We conclude that ivabradine improved survival in isoproterenol-damaged hearts.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2021

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Fundamental &amp; Clinical Pharmacology

ISSN

0767-3981

e-ISSN

—

Volume of the periodical

35

Issue of the periodical within the volume

4

Country of publishing house

GB - UNITED KINGDOM

Number of pages

5

Pages from-to

744-748

UT code for WoS article

000587113200001

EID of the result in the Scopus database

2-s2.0-85096648112